Novartis Ag

Baltazar Gomez-Mancilla

Donald Johns

Dominik Feuerbach

Fabrizio Gasparini

Kevin Hall McAllister

Cristina Lopez-Lopez

Yunsheng He

Markus Weiss

Nicole Pezous

Lisa Sandford

Kevin Hall Mcallister

Thérèse Di Paolo

Ricardo Carl Elciario Dolmetsch

Markus Fendt

Thérése Di Paolo

Daniel Umbricht

The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.

Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.

Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.

Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment

The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

Use of nicotinic acetylcholine receptor alpha 7 activators

The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.

Combination products

Growing community of inventors

Basel, Switzerland

Baltazar Gomez-Mancilla